Celmatix Announces Breakthrough in Novel Oral Fertility Drug Program
Celmatix Inc., the leading women’s health biotechnology company focused on ovarian biology, today announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor (FSHR) agonist drug.
- Celmatix Inc., the leading women’s health biotechnology company focused on ovarian biology, today announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor (FSHR) agonist drug.
- Therefore, a successful oral FSHR drug must stimulate the FSH receptor without stimulating the thyroid hormone receptor (TSHR).
- Early Celmatix data suggests that their unique, rationally designed compounds overcome this significant hurdle to drug development for this target.
- Celmatix Chief Scientific Officer, Dr. Stephen Palmer, notes, “We are very pleased to see that several of our novel compounds demonstrate the desired potency and selectivity required for a successful oral FSH drug.